Tumor-Infiltrating Lymphocytes/Plasmocytes in Chemotherapeutically Non-Influenced Triple-Negative Breast Cancers – Correlation with Morphological and Clinico-Pathological Parameters

Czech version

Authors: Markéta Kolečková ¹; Zdeněk Kolář ^1,2; Jiří Ehrmann ¹; Gabriela Kořínková ¹; Nora Zlámalová ³; Bohuslav Melichar ⁴; Radek Trojanec ²
Authors‘ workplace: Ústav klinické a molekulární patologie, LF UP a FN Olomouc ¹; Ústav molekulární a translační medicíny, LF UP a FN Olomouc ²; I. chirurgická klinika LF UP a FN Olomouc 4 Onkologická klinika LF UP a FN Olomouc ³
Published in: Klin Onkol 2019; 32(5): 380-387
Category: Original Articles
doi: https://doi.org/10.14735/amko2019380

Overview

Background: Triple-negative breast cancers (TNBCs) are considered a morphologically heterogeneous group of breast carcinomas characterized by the absence or low protein expression of hormone receptors and HER2/neu/ERBB2 with a specific biological behavior and therapeutic response. This study aimed to evaluate correlations of the density of tumor-infiltrating lymphocytes/plasmocytes (TILs) in the tumor parenchyma, stroma, and invasive margins with tumor morphology, the proliferation rate, Bcl-2 expression, and selected clinical and pathological parameters in early breast cancer patients prior to mastectomy who had not received initial chemotherapy.

Materials and methods: Samples of 3,544 breast cancer patients investigated in our department between 2007 and 2017 were re-examined. In total, 413 (11.65%) patients were diagnosed with TNBC. Only 61 cases did not undergo neoadjuvant therapy prior to mastectomy. Correlations between the density of TILs and tumor morphology, Bcl-2 expression, proliferative activity measured by Ki-67, patient age at diagnosis, tumor grade, and metastases were investigated.

Results: The samples were predominantly relatively well-localized invasive carcinomas of no special type with medullary features (80.32%) that measured on average 13.4 mm (range 5–20 mm, median 15 mm) and exhibited central necrosis or fibrosis, a tendency to undergo spindle cell and/or apocrine-like differentiation, and intensive infiltration of TILs. There were significant positive correlations between TILs and premenopausal status (p=0.003), Ki-67 expression (p=0.015), and tumor grade (p=0.002), a marginal positive correlation between TILs and tumor size (p=0.065), and a significant negative correlation between TILs and Bcl-2 expression (p=0.035). In younger patients (< 50 years) with tumor size less than or equal to 20 mm (pT1a–pT1c) we recorded a lower number of women with metastatic lymph node involvement (p=0.001).

Conclusion: The density and location of TILs in non-therapeutically influenced TNBCs, evaluated in the context of morphological changes and other clinicopathological parameters, may have prognostic significance and assist effective therapy planning.

Keywords:

triple-negative breast neoplasms – malignant neoplasm of breast – Mastectomy – tumor morphology – tumor infiltrating lymphocytes – Bcl-2 – clinico-pathological parameters

Sources

1. Lebert JM, Lester R, Powell E et al. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol 2018; 25 (Suppl 1): S142–S150. doi: 10.3747/co.25.3954.

2. Svoboda M, Navrátil J, Fabián P et al. Triple negativní karcinom prsu: analýza souboru pacientek diagnostikovaných a/nebo léčených v Masarykově onkologickém ústavu v letech 2004 až 2009. Klinická onkologie 2012; 25 (3): 188–198. doi: 10.14735/amko2012188.

3. Morris GJ, Naidu S, Topham AK et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer 2007; 110 (4): 876–884. doi: 10.1002/cncr.22836.

4. Ma CX, Luo J, Ellis MJ. Molecular profiling of triple negative breast cancer. Breast Dis 2010; 31 (1–2): 73–84. doi: 10.3233/BD-2010-0309.

5. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121 (7): 2750–2767. doi: 10.1172/JCI45014.

6. Zeng Z, Hou CHJ, Hu QH et al. Mammograhy and ultrasound effective features in differentiating basal-like and normal-like subtypes of triple-negative breast cancer. Oncotarget 2017; 8 (45): 79670–79679. doi: 10.18632/oncotarget.19053.

7. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26 (15): 2568–2581. doi: 10.1200/JCO.2007.13.1748.

8. Yadav BS, Chanana P, Jhamb S. Biomarkers in triple negative breast cancer: a review. World J Clin Oncol 2015; 6 (6): 252–263. doi: 10.5306/wjco.v6.i6.252.

9. Rampurwala M, Wisinski KB, O’Regan R. Role of the androgen receptor in triple-negative breast cancer. Clin Adv Hematol Oncol 2016; 14 (3): 186–193.

10. Liu D, He J, Yuan Z et al. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 2012; 29 (2): 401–405. doi: 10.1007/s12032-011-9827-x.

11. Domagala P, Huzarski T, Lubinski J et al. PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat 2011; 127 (3): 861–869. doi: 10.1007/s10549-011-1441-2.

12. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010; 21 (1): 21–26. doi: 10.1016/j.cytogfr.2009.11.003.

13. Luo J, Zhao Q, Zhang W et al. A novel panel of microRNAs provides a sensitive and specific tool for the diagnosis of breast cancer. Mol Med Rep 2014; 10 (2): 785–791. doi: 10.3892/mmr.2014.2274.

14. Lin A, Li C, Xing Z et al. The LINK-A lncRNA activates normoxic HIF1 signalling in triple-negative breast cancer. Nat Cell Biol 2016; 18 (2): 213–224. doi: 10.1038/ncb3295.

15. García-Teijido P, Luque Cabal M, Peláez Ferandéz I et al. Tumor-infiltrating lymhocytes in triple negative breast cancer: the future of immune targeting. Clinical Medicine Insights Oncology 2016; 10 (Suppl 1): 31–39. doi: 10.4137/CMO.S34540.

16. Bouchalova K, Svoboda M, Kharaishvili G et al. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. Tumour Biol 2015; 36 (6): 4243–4252. doi: 10.1007/s13277-015-3061-7.

17. Lakhani SR, Ellis IO, Schnitt SJ et al. WHO classification of tumours of the breast. WHO Classification of Tumours. 4th ed. Lyon, IARC Press 2012.

18. Denkert C, Wienert S, Poterie A et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol 2016; 29 (10): 1155–1164. doi: 10.1038/modpathol.2016.109.

19. Salgado R, Denkert C, Demaria S et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26 (2): 259–271. doi: 10.1093/annonc/mdu450.

20. Polónia A, Pinto R, Cameselle-Teijeiro JF et al. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. J Clin Pathol 2017; 70 (10): 860–867. doi: 10.1136/jclinpath-2016-203990.

21. Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology 2017; 49 (2): 166–171. doi: 10.1016/j.pathol.2016.11.006.

22. Ilie SM, Bacinschi XE, Botnariuc I. Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis. Breast Cancer (Dove Med Press) 2018; 10: 177–194. doi: 10.2147/BCTT.S175556.

23. Zenzola V, Cabezas-Quintario MA, Arguelles M et al. Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer. Clin Transl Oncol 2018; 20 (11): 1448–1454. doi: 10.1007/s12094-018-18 77-5.

24. Dowsett M, Nielsen TO, A’Hern R et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103 (22): 1656–1664. doi: 10.1093/jnci/djr393.

25. Mao Y, Qu Q, Zhang Y et al. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One 2014; 9 (12): e115103. doi: 10.1371/journal.pone.0115103.

26. Rechsteiner M, Dedes K, Fink D et al. Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features. J Cancer Res Clin Oncol 2018; 144 (5): 865–874. doi: 10.1007/s00432-018-2609-5.

27. Zhao S, Ma D, Xiao Y et al. Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: a large population-based analysis. Eur J Surg Oncol 2018; 44 (4): 420–428. doi: 10.1016/ j.ejso.2017.11.027.

28. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28 (1): 105–113. doi: 10.1200/JCO.2009.23.7370.

29. Ono M, Tsuda H, Shimizu C et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat 2012; 132 (3): 793–805. doi: 10.1007/s10549-011-1554-7.

30. Yamaguchi R, Tanaka M, Yano A et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Human Pathol 2012; 43 (10): 1688–1694. doi: 10.1016/j.humpath.2011.12.013.

31. Ladoire S, Arnould L, Apetoh L et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 2008; 14 (8): 2413–2420. doi: 10.1158/1078-0432.CCR-07-4491.